Zevra Therapeutics, Inc. ZVRA Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $124.22M+235% | $83.23M+179% | $35.33M+139% | $2.64M+104% | -$91.99M-86.0% | ||
| $2.77M-57.2% | $4.05M-36.5% | $5.34M-3.4% | $6.57M+65.2% | $6.48M+160% | ||
| $12.62M-20.6% | $12.63M-15.2% | $12.37M+0.1% | $15.73M+107% | $15.9M+123% | ||
| —— | —— | —— | —— | $0— | ||
| $1.29M-80.2% | $1.31M-85.3% | $5.5M+32.6% | $5.88M+68.4% | $6.49M+167% | ||
| -$9.26M— | -$16M— | —— | —— | —— | ||
| -$2.22M-572% | -$451K— | $3.34M— | -$566K— | -$330K— | ||
| -$1.3M-177% | -$1.16M-239% | $6.69M— | $2.49M— | $1.69M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $414K— | ||
| —— | —— | —— | —— | —— | ||
| -$608K+11.4% | -$675K-7.8% | -$777K-53.0% | $398K+179% | -$686K-48.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$46.21M+17.6% | -$61.72M-35.2% | ||
| $802K+710% | $866K— | $866K+1,103% | $312K+27.9% | $99K-62.9% | ||
| $360.92M+644% | $309.99M+653% | $263.98M+1,195% | $198.74M+598% | $48.52M+71.2% | ||
| $254.47M+802% | $178.5M+614% | $91.2M+126% | $40.71M+2.0% | $28.21M— | ||
| —— | $0-100% | $1.5M-66.7% | $3M0.0% | $4.5M+200% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$14.35M— | -$26.41M— | ||
| $60.09M— | $0— | —— | —— | —— | ||
| $752K— | $0— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$42.35M-151% | $12.06M-85.3% | $10.31M-88.1% | $68.55M+43.4% | $82.5M+147% | ||
| —— | —— | $1.02M+673% | $466K-10.6% | $127K+292% | ||
| $58.26M+1,157% | $28.62M+409% | $400K-96.3% | $8.45M+131% | -$5.51M-306% | ||
| $5.39M-16.1% | $5.33M+1.3% | $5.59M+52.3% | $5.75M+147% | $6.43M+1,117% | ||
| $3.45M+188% | $3.13M+251% | $3.16M— | $1.95M— | $1.2M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $64K+1,167% | -$149K-928% | -$37K+83.6% | -$3K+98.8% | -$6K+98.5% | ||
| —— | —— | —— | —— | —— | ||
| $1.73M— | -$2.18M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $18.76M— | $16.56M— | ||
| —— | —— | —— | —— | —— | ||
| -$608K+11.4% | -$675K-7.8% | -$777K-53.0% | $398K+179% | -$686K-48.5% | ||
| —— | —— | —— | —— | —— | ||
| -$1.3M-177% | -$1.16M-239% | $6.69M— | $2.49M— | $1.69M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $5.12M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $12.19M+114% | $11.7M+104% | $12.2M+133% | $14.2M+338% | $5.7M+12,859% | ||
| —— | —— | —— | —— | $414K— | ||
| —— | —— | —— | —— | —— | ||
| —— | $0-100% | $1.5M-66.7% | $3M0.0% | $4.5M+200% | ||
| $360.92M+639% | $309.99M+647% | $222.82M+321% | $199.07M+764% | $48.85M+42.2% | ||
| $254.47M+802% | $178.5M+614% | $91.2M+126% | $40.71M+2.0% | $28.21M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $60.09M— | $0— | —— | —— | —— | ||
| —— | —— | $1.02M+673% | $466K-10.6% | $127K+292% | ||
| -$608K+11.4% | -$675K-7.8% | -$777K-53.0% | $398K+179% | -$686K-48.5% | ||
| —— | —— | —— | —— | $1.53M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$46.53M+17.4% | -$61.82M-34.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Zevra Therapeutics, Inc. generate?
- Zevra Therapeutics, Inc. (ZVRA) generated -$21.9M in operating cash flow over the trailing twelve months.
- What is Zevra Therapeutics, Inc.'s free cash flow?
- After $802.0K of capital expenditures, Zevra Therapeutics, Inc.'s free cash flow was -$22.3M over the trailing twelve months, up 68.0% year over year.
- Where does Zevra Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
